Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Human Capital & Careers
Salary Transparency’s Impact On the Future of Labor
With salary ranges being required in more areas, how can executives use these new laws to better their hiring practices?
By
Adam Zaki
| February 3, 2023
Read More
Resources
CFO Live
2022 Survey
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
2022 Survey
Sign Up
Sponsored by
drug costs
Human Capital
Employer Group Launches Its Own PBM
EmsanaRx aims to address “the lack of accountability of the PBM industry to its employer clients."
By
Matthew Heller
| October 25, 2021
Read More
Human Capital & Careers
Specialty Drug Costs to Soar Again in 2018
The rate of spending increase on high-tech pharmaceuticals will top 17% for a second consecutive year, a study says.
By
David McCann
| September 22, 2017
Read More
Risk & Compliance
How to Rein In the Soaring Costs of Specialty Drugs
The 420-employer National Business Group on Health recommends public-policy changes relating to the proliferating category of specialty drugs.
By
David McCann
| January 30, 2017
Read More
Human Capital & Careers
Specialty Drugs Drive Health Care Cost Trend
Health benefits costs are forecast to climb 5% next year, thanks in part to fast-rising prices for specialty pharmaceuticals.
By
David McCann
| August 9, 2016
Read More
Strategy
Walgreens Buys Rite Aid for $9.4 Billion
The combination of two of the three largest U.S. drug store chains continues a wave of industry consolidation spurred by the Affordable Care Act.
By
Katie Kuehner-Hebert
| October 28, 2015
Read More
Human Capital & Careers
Specialty Drugs Eat More of Health-Care Spending Pie
Thanks to a proliferation of high-cost drugs for complex conditions, pharmacy expenses outpace overall medical cost growth.
By
David McCann
| February 25, 2015
Read More
Risk & Compliance
Drug Prices: Costly Cures
An American fight over expensive new treatments has global implications.
By
Economist Staff
| June 9, 2014
Read More